GlaxoSmithKline Plc’s Defensive Properties Make It A ‘Buy’ For Me

I’m thinking of adding to my stake in GlaxoSmithKline plc (LON: GSK) in these uncertain times.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the US ‘default deadline’ set at 17 October, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) looks to be the perfect stock to buy because it has superb defensive qualities.

Indeed, should things not be resolved in the US, I want to be invested in stocks that are likely to fall less than the market does (assuming the market falls, of course). So, top of my ‘buy list’ is GlaxoSmithKline.

One way to assess the amount of any share price fall is through a stock’s beta, with a beta of less than 1 suggesting that a market fall will be more severe than a stock’s fall. GlaxoSmithKline’s beta of 0.75 fits the bill perfectly and means that, should this be the start of a bearish period for shares, I should be better protected on the downside than had I been invested in the general market.

Of course, superb defensive qualities are not the only reason why I’m bullish on GlaxoSmithKline.

Indeed, the company’s ability to deliver high and consistent return on equity is highly relevant and shows that the business is capable of generating excellent returns for its shareholders.

In the last year, for instance, return on equity was an extremely high 70%. Furthermore, this figure has been above 50% in four of the last five years, with 2010 being the one blot on the company’s report. However, even in 2010 (when a £4 billion payment for legal disputes hit profit hard) return on equity was still relatively impressive, being 19%.

In addition, I believe that buying shares in GlaxoSmithKline at this moment in time would mean getting ahead of the curve. Negative news flow surrounding the alleged bribery investigation in China has weighed on shares, but this is unlikely to last in the long run.

Furthermore, I feel it will just be a matter of time before the market once again focuses on the success the company is having with its drug pipeline and the approvals process. This, rather than the outcome of a Chinese bribery investigation, is likely to be a long-term driver of the share price.

So, I’m keen on the idea of adding to my position in GlaxoSmithKline because of its excellent defensive qualities, as represented by its low beta. I’m also impressed by its high — and consistent — return on equity as well as the feeling that I would be getting ahead of the curve, were I to buy shares now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Peter owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »